References
- Global strategy for asthma management and prevention. 2020. https://ginasthma.org/ [last accessed 21 April 2020].
- Global strategy for asthma management and prevention. 2019. https://ginasthma.org/ [last accessed 21 April 2020].
- Gupta N, Agrawal S, Ish P, Mishra S, Gaind R, Usha G, Singh B, Sen MK, Safdarjung Hospital COVID 2019 working group. Clinical and epidemiologic profile of the initial COVID-19 patients at a tertiary care centre in India. Monaldi Arch Chest Dis. 2020;90(1). doi:https://doi.org/10.4081/monaldi.2020.1294.
- NIOX VERO® Products Coronavirus FAQ. https://www.niox.com/en/coronavirus-faq/ [last accessed on 30 May 2020].
- O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK, et al. Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med. 2018;378(20):1865–1876. doi:https://doi.org/10.1056/NEJMoa1715274.
- Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM, et al. As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med. 2018;378(20):1877–1887. doi:https://doi.org/10.1056/NEJMoa1715275.
- Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med. 2019;380(21):2020–2030. doi:https://doi.org/10.1056/NEJMoa1901963.
- Hardy J, Baggott C, Fingleton J, Reddel HK, Hancox RJ, Harwood M, Corin A, Sparks J, Hall D, Sabbagh D, PRACTICAL study team, et al. Budesonide-formoterol reliever therapy versus maintenance budesonide plus terbutaline reliever therapy in adults with mild to moderate asthma (PRACTICAL): a 52-week, open-label, multicentre, superiority, randomised controlled trial. Lancet. 2019;394(10202):919–998. doi:https://doi.org/10.1016/S0140-6736(19)31948-8.
- Philip G, Hustad C, Noonan G, Malice M-P, Ezekowitz A, Reiss TF, Knorr B. Reports of suicidality in clinical trials of montelukast. J Allergy Clin Immunol. 2009;124(4):691–696.e6. doi:https://doi.org/10.1016/j.jaci.2009.08.010.
- FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast; advises restricting use for allergic rhinitis. https://www.fda.gov/drugs/drug-safety-and-availability/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug [last accessed 22 April 2020]
- Gupta A, Ikeda M, Geng B, Azmi J, Price RG, Bradford ES, Yancey SW, Steinfeld J. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019;144(5):1336–1342.e7. doi:https://doi.org/10.1016/j.jaci.2019.08.005.
- Achakulwisut P, Brauer M, Hystad P, Anenberg SC. Global, national, and urban burdens of paediatric asthma incidence attributable to ambient NO2 pollution: estimates from global datasets. Lancet Planet Health. 2019;3(4):e166–e178. doi:https://doi.org/10.1016/S2542-5196(19)30046-4.